epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Cysto-Conray II

iothalamate meglumine

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Adult Dosing .

Dosage forms:  INJ: 81 mg per mL

Special Note

[strength clarification]
Info: strength expressed as iodine concentration

retrograde cystography

[200-400 mL intravesically x1]

retrograde cystourethrography

[200-400 mL intravesically x1]

renal dosing

[not defined]
renal impairment: not defined
HD/PD: not defined

hepatic dosing

[not defined]

Peds Dosing .

Dosage forms:  INJ: 81 mg per mL

Special Note

[strength clarification]
Info: strength expressed as iodine concentration

retrograde cystography

[30-300 mL intravesically x1]

retrograde cystourethrography

[30-300 mL intravesically x1]

renal dosing

[not defined]
renal impairment: not defined
HD/PD: not defined

hepatic dosing

[not defined]

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@437f6f43
  • intrathecal use
  • intravascular use
  • caution: hypersensitivity to drug or ingredient
  • caution: hypersensitivity to other iodinated contrast media
  • caution: asthma
  • caution: allergies, known
  • caution: UTI, active

Drug Interactions .

Overview

iothalamate meglumine

contrast agent

Interaction Characteristics:
  • nephrotoxicity
  • thrombogenic effects
Other Info
  • caution advised with radioactive iodine; iothalamate meglumine may decrease thyroid uptake of radioactive iodine, efficacy

Contraindicated

  • cidofovir
  • Cysto-Conray II (iothalamate meglumine)
    +
    cidofovir
    1 interaction

    Contraindicated

    iothalamate meglumine + cidofovir

    contraindicated; D/C IV iothalamate meglumine at least 7 days prior to cidofovir use; retrograde cystography and cystourethrography use OK: combo may incr. cidofovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

Avoid/Use Alternative

  • aldesleukin
  • Cysto-Conray II (iothalamate meglumine)
    +
    aldesleukin
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + aldesleukin

    use alternative or monitor renal function if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • amikacin
  • Cysto-Conray II (iothalamate meglumine)
    +
    amikacin
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + amikacin

    use alternative or monitor amikacin levels, renal function, ototoxicity if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • amikacin inhaled
  • Cysto-Conray II (iothalamate meglumine)
    +
    amikacin inhaled
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + amikacin inhaled

    use alternative or monitor renal function, ototoxicity if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • bumetanide
  • Cysto-Conray II (iothalamate meglumine)
    +
    bumetanide
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + bumetanide

    use alternative or monitor renal function if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • clofarabine
  • Cysto-Conray II (iothalamate meglumine)
    +
    clofarabine
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + clofarabine

    avoid IV iothalamate meglumine use during 5 day clofarabine tx; monitor CBC, renal function, BP; retrograde cystography and cystourethrography use OK: combo may incr. clofarabine levels, risk of serious infection, myelosuppression, nephrotoxicity, hypotension, other adverse effects (additive effects)

  • foscarnet
  • Cysto-Conray II (iothalamate meglumine)
    +
    foscarnet
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + foscarnet

    use alternative or monitor CBC, renal function if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. foscarnet levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • ganciclovir
  • Cysto-Conray II (iothalamate meglumine)
    +
    ganciclovir
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + ganciclovir

    use alternative or monitor CBC, renal function if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • iodixanol
  • Cysto-Conray II (iothalamate meglumine)
    +
    iodixanol
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + iodixanol

    use alternative or monitor renal function, thrombosis signs/symptoms: combo may incr. risk of nephrotoxicity, thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • iohexol
  • Cysto-Conray II (iothalamate meglumine)
    +
    iohexol
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + iohexol

    use alternative or monitor renal function, thrombosis signs/symptoms: combo may incr. risk of nephrotoxicity, thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • iomeprol
  • Cysto-Conray II (iothalamate meglumine)
    +
    iomeprol
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + iomeprol

    use alternative or monitor renal function, thrombosis signs/symptoms: combo may incr. risk of nephrotoxicity, thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • iopamidol
  • Cysto-Conray II (iothalamate meglumine)
    +
    iopamidol
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + iopamidol

    use alternative or monitor renal function, thrombosis signs/symptoms: combo may incr. risk of nephrotoxicity, thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • iopromide
  • Cysto-Conray II (iothalamate meglumine)
    +
    iopromide
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + iopromide

    use alternative or monitor renal function, thrombosis signs/symptoms: combo may incr. risk of nephrotoxicity, thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • iothalamate meglumine
  • Cysto-Conray II (iothalamate meglumine)
    +
    iothalamate meglumine
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + iothalamate meglumine

    avoid combo: combo may incr. risk of nephrotoxicity, thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • ioversol
  • Cysto-Conray II (iothalamate meglumine)
    +
    ioversol
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + ioversol

    use alternative or monitor renal function, thrombosis signs/symptoms: combo may incr. risk of nephrotoxicity, thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • oxaliplatin
  • Cysto-Conray II (iothalamate meglumine)
    +
    oxaliplatin
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + oxaliplatin

    use alternative or monitor ECG, CBC, renal function, ototoxicity if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. oxaliplatin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • pentamidine
  • Cysto-Conray II (iothalamate meglumine)
    +
    pentamidine
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + pentamidine

    if IV iothalamate meglumine use, use alternative or monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • polymyxin B
  • Cysto-Conray II (iothalamate meglumine)
    +
    polymyxin B
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + polymyxin B

    avoid combo: combo may incr. risk of nephrotoxicity (additive effects)

  • streptomycin
  • Cysto-Conray II (iothalamate meglumine)
    +
    streptomycin
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + streptomycin

    use alternative or monitor renal function, ototoxicity if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. streptomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • streptozocin
  • Cysto-Conray II (iothalamate meglumine)
    +
    streptozocin
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + streptozocin

    use alternative or monitor renal function if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • tobramycin
  • Cysto-Conray II (iothalamate meglumine)
    +
    tobramycin
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + tobramycin

    use alternative or monitor tobramycin levels, renal function, ototoxicity if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • tobramycin inhaled
  • Cysto-Conray II (iothalamate meglumine)
    +
    tobramycin inhaled
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + tobramycin inhaled

    use alternative or monitor renal function, ototoxicity if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • tranexamic acid
  • Cysto-Conray II (iothalamate meglumine)
    +
    tranexamic acid
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + tranexamic acid

    if IV iothalamate meglumine use, avoid combo; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • vaccinia immune globulin
  • Cysto-Conray II (iothalamate meglumine)
    +
    vaccinia immune globulin
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + vaccinia immune globulin

    use alternative or monitor renal function, thrombosis signs/symptoms if IV iothalamate meglumine use; use lowest vaccinia immune globulin concentration and infusion rate possible; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • valganciclovir
  • Cysto-Conray II (iothalamate meglumine)
    +
    valganciclovir
    1 interaction

    Avoid/Use Alternative

    iothalamate meglumine + valganciclovir

    use alternative or monitor CBC, renal function if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

Monitor/Modify Tx

  • abemaciclib
  • Cysto-Conray II (iothalamate meglumine)
    +
    abemaciclib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + abemaciclib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • abrocitinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    abrocitinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + abrocitinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • acyclovir
  • Cysto-Conray II (iothalamate meglumine)
    +
    acyclovir
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + acyclovir

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • adefovir dipivoxil
  • Cysto-Conray II (iothalamate meglumine)
    +
    adefovir dipivoxil
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + adefovir dipivoxil

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. adefovir levels, risk of nephrotoxicity, other adverse effects (renal excretion decreased by nephrotoxic agents, additive effects)

  • aflibercept
  • Cysto-Conray II (iothalamate meglumine)
    +
    aflibercept
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + aflibercept

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • alectinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    alectinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + alectinib

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • aliskiren
  • Cysto-Conray II (iothalamate meglumine)
    +
    aliskiren
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + aliskiren

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • allopurinol
  • Cysto-Conray II (iothalamate meglumine)
    +
    allopurinol
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + allopurinol

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • amiloride
  • Cysto-Conray II (iothalamate meglumine)
    +
    amiloride
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + amiloride

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • aminocaproic acid
  • Cysto-Conray II (iothalamate meglumine)
    +
    aminocaproic acid
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + aminocaproic acid

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • amphotericin
  • Cysto-Conray II (iothalamate meglumine)
    +
    amphotericin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + amphotericin

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • angiotensin II
  • Cysto-Conray II (iothalamate meglumine)
    +
    angiotensin II
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + angiotensin II

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • anthrax immune globulin
  • Cysto-Conray II (iothalamate meglumine)
    +
    anthrax immune globulin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + anthrax immune globulin

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest anthrax immune globulin infusion rate possible; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • anti-inhibitor coagulant complex
  • Cysto-Conray II (iothalamate meglumine)
    +
    anti-inhibitor coagulant complex
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + anti-inhibitor coagulant complex

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with anti-inhibitor coagulant complex dose >100 units/kg; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • antihemophilic factor (factor VIII)/von Willebrand factor complex
  • Cysto-Conray II (iothalamate meglumine)
    +
    antihemophilic factor (factor VIII)/ von Willebrand factor complex
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + antihemophilic factor (factor VIII)/ von Willebrand factor complex

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • asciminib
  • Cysto-Conray II (iothalamate meglumine)
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + asciminib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • asparaginase
  • Cysto-Conray II (iothalamate meglumine)
    +
    asparaginase
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + asparaginase

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • aspirin
  • Cysto-Conray II (iothalamate meglumine)
    +
    aspirin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + aspirin

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • atidarsagene autotemcel
  • Cysto-Conray II (iothalamate meglumine)
    +
    atidarsagene autotemcel
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + atidarsagene autotemcel

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • auranofin
  • Cysto-Conray II (iothalamate meglumine)
    +
    auranofin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + auranofin

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. auranofin levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • avatrombopag
  • Cysto-Conray II (iothalamate meglumine)
    +
    avatrombopag
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + avatrombopag

    if IV iothalamate meglumine use, monitor platelets, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • axitinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    axitinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + axitinib

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • azilsartan medoxomil
  • Cysto-Conray II (iothalamate meglumine)
    +
    azilsartan medoxomil
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + azilsartan medoxomil

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • balsalazide
  • Cysto-Conray II (iothalamate meglumine)
    +
    balsalazide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + balsalazide

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • baricitinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    baricitinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + baricitinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • bazedoxifene
  • Cysto-Conray II (iothalamate meglumine)
    +
    bazedoxifene
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + bazedoxifene

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • benazepril
  • Cysto-Conray II (iothalamate meglumine)
    +
    benazepril
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + benazepril

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • bevacizumab
  • Cysto-Conray II (iothalamate meglumine)
    +
    bevacizumab
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + bevacizumab

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • binimetinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    binimetinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + binimetinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • bleomycin
  • Cysto-Conray II (iothalamate meglumine)
    +
    bleomycin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + bleomycin

    if IV iothalamate meglumine use, monitor renal function; decr. bleomycin dose based on CrCl; retrograde cystography and cystourethrography use OK: combo may incr. bleomycin levels, risk of pulmonary toxicities (including life-threatening), other adverse effects (renal excretion decreased)

  • botulism immune globulin
  • Cysto-Conray II (iothalamate meglumine)
    +
    botulism immune globulin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + botulism immune globulin

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest botulism immune globulin concentration and infusion rate possible; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • brolucizumab
  • Cysto-Conray II (iothalamate meglumine)
    +
    brolucizumab
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + brolucizumab

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • C1 esterase inhibitor
  • Cysto-Conray II (iothalamate meglumine)
    +
    C1 esterase inhibitor
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + C1 esterase inhibitor

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • cabozantinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    cabozantinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + cabozantinib

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • calaspargase
  • Cysto-Conray II (iothalamate meglumine)
    +
    calaspargase
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + calaspargase

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • candesartan cilexetil
  • Cysto-Conray II (iothalamate meglumine)
    +
    candesartan cilexetil
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + candesartan cilexetil

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • capecitabine
  • Cysto-Conray II (iothalamate meglumine)
    +
    capecitabine
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + capecitabine

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • captopril
  • Cysto-Conray II (iothalamate meglumine)
    +
    captopril
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + captopril

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • carboplatin
  • Cysto-Conray II (iothalamate meglumine)
    +
    carboplatin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + carboplatin

    if IV iothalamate meglumine use, monitor CBC, renal function, ototoxicity; retrograde cystography and cystourethrography use OK: combo may incr. carboplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • carfilzomib
  • Cysto-Conray II (iothalamate meglumine)
    +
    carfilzomib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + carfilzomib

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • celecoxib
  • Cysto-Conray II (iothalamate meglumine)
    +
    celecoxib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + celecoxib

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective celecoxib dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • chlorothiazide
  • Cysto-Conray II (iothalamate meglumine)
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + chlorothiazide

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • chlorthalidone
  • Cysto-Conray II (iothalamate meglumine)
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + chlorthalidone

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • chorionic gonadotropin
  • Cysto-Conray II (iothalamate meglumine)
    +
    chorionic gonadotropin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + chorionic gonadotropin

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • cisplatin
  • Cysto-Conray II (iothalamate meglumine)
    +
    cisplatin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + cisplatin

    if IV iothalamate meglumine use, monitor CBC, renal function, ototoxicity; retrograde cystography and cystourethrography use OK: combo may incr. cisplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • clindamycin
  • Cysto-Conray II (iothalamate meglumine)
    +
    clindamycin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + clindamycin

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • clozapine
  • Cysto-Conray II (iothalamate meglumine)
    +
    clozapine
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + clozapine

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • coagulation factor IX
  • Cysto-Conray II (iothalamate meglumine)
    +
    coagulation factor IX
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + coagulation factor IX

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • coagulation factor VIIa
  • Cysto-Conray II (iothalamate meglumine)
    +
    coagulation factor VIIa
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + coagulation factor VIIa

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • coagulation factor XIII A-subunit
  • Cysto-Conray II (iothalamate meglumine)
    +
    coagulation factor XIII A-subunit
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + coagulation factor XIII A-subunit

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • colistimethate
  • Cysto-Conray II (iothalamate meglumine)
    +
    colistimethate
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + colistimethate

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. colistimethate levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • concizumab
  • Cysto-Conray II (iothalamate meglumine)
    +
    concizumab
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + concizumab

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • copper histidinate
  • Cysto-Conray II (iothalamate meglumine)
    +
    copper histidinate
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + copper histidinate

    if IV iothalamate meglumine use, monitor renal function, electrolytes; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • creatine
  • Cysto-Conray II (iothalamate meglumine)
    +
    creatine
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + creatine

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • cyclophosphamide
  • Cysto-Conray II (iothalamate meglumine)
    +
    cyclophosphamide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + cyclophosphamide

    if IV iothalamate meglumine use, monitor CBC, renal, cardiac function; retrograde cystography and cystourethrography use OK: combo may incr. cyclophosphamide levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)

  • cyclosporine
  • Cysto-Conray II (iothalamate meglumine)
    +
    cyclosporine
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + cyclosporine

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • cytomegalovirus immune globulin
  • Cysto-Conray II (iothalamate meglumine)
    +
    cytomegalovirus immune globulin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + cytomegalovirus immune globulin

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest cytomegalovirus immune globulin concentration and infusion rate possible; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • danazol
  • Cysto-Conray II (iothalamate meglumine)
    +
    danazol
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + danazol

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • darbepoetin alfa
  • Cysto-Conray II (iothalamate meglumine)
    +
    darbepoetin alfa
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + darbepoetin alfa

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • deferasirox
  • Cysto-Conray II (iothalamate meglumine)
    +
    deferasirox
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + deferasirox

    if IV iothalamate meglumine use, monitor CBC, renal function, ototoxicity; retrograde cystography and cystourethrography use OK: combo may incr. deferasirox levels, risk of myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • deferoxamine
  • Cysto-Conray II (iothalamate meglumine)
    +
    deferoxamine
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + deferoxamine

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • deflazacort
  • Cysto-Conray II (iothalamate meglumine)
    +
    deflazacort
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + deflazacort

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • desogestrel (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    desogestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + desogestrel (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • deuruxolitinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    deuruxolitinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + deuruxolitinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • dexamethasone
  • Cysto-Conray II (iothalamate meglumine)
    +
    dexamethasone
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + dexamethasone

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially if multiple myeloma use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • diclofenac
  • Cysto-Conray II (iothalamate meglumine)
    +
    diclofenac
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + diclofenac

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective diclofenac dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • diclofenac topical
  • Cysto-Conray II (iothalamate meglumine)
    +
    diclofenac topical
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + diclofenac topical

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective diclofenac dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • dienogest (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    dienogest (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + dienogest (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • diflunisal
  • Cysto-Conray II (iothalamate meglumine)
    +
    diflunisal
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + diflunisal

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective diflunisal dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • drospirenone (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    drospirenone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + drospirenone (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • drospirenone (hormone replacement)
  • Cysto-Conray II (iothalamate meglumine)
    +
    drospirenone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + drospirenone (hormone replacement)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • eltrombopag
  • Cysto-Conray II (iothalamate meglumine)
    +
    eltrombopag
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + eltrombopag

    if IV iothalamate meglumine use, monitor platelets, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • enalapril
  • Cysto-Conray II (iothalamate meglumine)
    +
    enalapril
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + enalapril

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • enalaprilat
  • Cysto-Conray II (iothalamate meglumine)
    +
    enalaprilat
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + enalaprilat

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • epirubicin
  • Cysto-Conray II (iothalamate meglumine)
    +
    epirubicin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + epirubicin

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • epoetin alfa
  • Cysto-Conray II (iothalamate meglumine)
    +
    epoetin alfa
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + epoetin alfa

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • estetrol (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    estetrol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + estetrol (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • estradiol (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + estradiol (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • estradiol (hormone replacement)
  • Cysto-Conray II (iothalamate meglumine)
    +
    estradiol (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + estradiol (hormone replacement)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • estrogens, conjugated (hormone replacement)
  • Cysto-Conray II (iothalamate meglumine)
    +
    estrogens, conjugated (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + estrogens, conjugated (hormone replacement)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • estrogens, esterified (hormone replacement)
  • Cysto-Conray II (iothalamate meglumine)
    +
    estrogens, esterified (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + estrogens, esterified (hormone replacement)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • ethacrynic acid
  • Cysto-Conray II (iothalamate meglumine)
    +
    ethacrynic acid
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ethacrynic acid

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • ethinyl estradiol (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ethinyl estradiol (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • ethinyl estradiol (hormone replacement)
  • Cysto-Conray II (iothalamate meglumine)
    +
    ethinyl estradiol (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ethinyl estradiol (hormone replacement)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • ethynodiol (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    ethynodiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ethynodiol (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • etodolac
  • Cysto-Conray II (iothalamate meglumine)
    +
    etodolac
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + etodolac

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective etodolac dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • etonogestrel (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    etonogestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + etonogestrel (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • everolimus
  • Cysto-Conray II (iothalamate meglumine)
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + everolimus

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • factor XIII concentrate
  • Cysto-Conray II (iothalamate meglumine)
    +
    factor XIII concentrate
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + factor XIII concentrate

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • faricimab
  • Cysto-Conray II (iothalamate meglumine)
    +
    faricimab
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + faricimab

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • fedratinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    fedratinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + fedratinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • fenofibrate
  • Cysto-Conray II (iothalamate meglumine)
    +
    fenofibrate
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + fenofibrate

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • fenofibric acid
  • Cysto-Conray II (iothalamate meglumine)
    +
    fenofibric acid
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + fenofibric acid

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • fenoprofen
  • Cysto-Conray II (iothalamate meglumine)
    +
    fenoprofen
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + fenoprofen

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective fenoprofen dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • fibrinogen (human)
  • Cysto-Conray II (iothalamate meglumine)
    +
    fibrinogen (human)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + fibrinogen (human)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • fitusiran
  • Cysto-Conray II (iothalamate meglumine)
    +
    fitusiran
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + fitusiran

    if IV iothalamate meglumine use, monitor antithrombin activity level, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • flucytosine
  • Cysto-Conray II (iothalamate meglumine)
    +
    flucytosine
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + flucytosine

    if IV iothalamate meglumine use, monitor CBC, renal function, flucytosine levels; retrograde cystography and cystourethrography use OK: combo may incr. flucytosine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • flurbiprofen
  • Cysto-Conray II (iothalamate meglumine)
    +
    flurbiprofen
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + flurbiprofen

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective flurbiprofen dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • follitropin
  • Cysto-Conray II (iothalamate meglumine)
    +
    follitropin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + follitropin

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • fosinopril
  • Cysto-Conray II (iothalamate meglumine)
    +
    fosinopril
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + fosinopril

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • fruquintinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    fruquintinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + fruquintinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • furosemide
  • Cysto-Conray II (iothalamate meglumine)
    +
    furosemide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + furosemide

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • gentamicin
  • Cysto-Conray II (iothalamate meglumine)
    +
    gentamicin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + gentamicin

    use alternative or monitor gentamicin levels, renal function, ototoxicity if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. gentamicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • hepatitis B immune globulin
  • Cysto-Conray II (iothalamate meglumine)
    +
    hepatitis B immune globulin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + hepatitis B immune globulin

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; use lowest hepatitis B immune globulin infusion rate possible; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • hydrochlorothiazide
  • Cysto-Conray II (iothalamate meglumine)
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + hydrochlorothiazide

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • hydroxocobalamin IV
  • Cysto-Conray II (iothalamate meglumine)
    +
    hydroxocobalamin IV
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + hydroxocobalamin IV

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • ibuprofen
  • Cysto-Conray II (iothalamate meglumine)
    +
    ibuprofen
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ibuprofen

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective ibuprofen dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • ibuprofen lysine
  • Cysto-Conray II (iothalamate meglumine)
    +
    ibuprofen lysine
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ibuprofen lysine

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • ifosfamide
  • Cysto-Conray II (iothalamate meglumine)
    +
    ifosfamide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ifosfamide

    if IV iothalamate meglumine use, monitor CBC, renal, cardiac function; retrograde cystography and cystourethrography use OK: combo may incr. ifosfamide levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)

  • immune globulin
  • Cysto-Conray II (iothalamate meglumine)
    +
    immune globulin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + immune globulin

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest immune globulin dose, concentration and infusion rate possible; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • indapamide
  • Cysto-Conray II (iothalamate meglumine)
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + indapamide

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • indomethacin
  • Cysto-Conray II (iothalamate meglumine)
    +
    indomethacin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + indomethacin

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective indomethacin dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • irbesartan
  • Cysto-Conray II (iothalamate meglumine)
    +
    irbesartan
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + irbesartan

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • ketoprofen
  • Cysto-Conray II (iothalamate meglumine)
    +
    ketoprofen
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ketoprofen

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective ketoprofen dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • ketorolac
  • Cysto-Conray II (iothalamate meglumine)
    +
    ketorolac
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ketorolac

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective ketorolac dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • lazertinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    lazertinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + lazertinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • lenalidomide
  • Cysto-Conray II (iothalamate meglumine)
    +
    lenalidomide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + lenalidomide

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • lenvatinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    lenvatinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + lenvatinib

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • levonorgestrel (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    levonorgestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + levonorgestrel (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • levonorgestrel (hormone replacement)
  • Cysto-Conray II (iothalamate meglumine)
    +
    levonorgestrel (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + levonorgestrel (hormone replacement)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • lifileucel
  • Cysto-Conray II (iothalamate meglumine)
    +
    lifileucel
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + lifileucel

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • lisinopril
  • Cysto-Conray II (iothalamate meglumine)
    +
    lisinopril
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + lisinopril

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • lithium
  • Cysto-Conray II (iothalamate meglumine)
    +
    lithium
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + lithium

    if IV iothalamate meglumine use, monitor lithium levels, renal function; retrograde cystography and cystourethrography use OK: combo may incr. lithium levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • lomustine
  • Cysto-Conray II (iothalamate meglumine)
    +
    lomustine
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + lomustine

    if IV iothalamate meglumine use, monitor CBC, renal function; retrograde cystography and cystourethrography use OK: combo may incr. lomustine levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • losartan
  • Cysto-Conray II (iothalamate meglumine)
    +
    losartan
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + losartan

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • luspatercept
  • Cysto-Conray II (iothalamate meglumine)
    +
    luspatercept
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + luspatercept

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms if beta thalassemia use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • lusutrombopag
  • Cysto-Conray II (iothalamate meglumine)
    +
    lusutrombopag
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + lusutrombopag

    if IV iothalamate meglumine use, monitor platelets, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • lutetium Lu 177 vipivotide tetraxetan
  • Cysto-Conray II (iothalamate meglumine)
    +
    lutetium Lu 177 vipivotide tetraxetan
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + lutetium Lu 177 vipivotide tetraxetan

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • magnesium citrate
  • Cysto-Conray II (iothalamate meglumine)
    +
    magnesium citrate
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + magnesium citrate

    if IV iothalamate meglumine use, monitor renal function, especially if magnesium citrate bowel prep use; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • magnesium salicylate
  • Cysto-Conray II (iothalamate meglumine)
    +
    magnesium salicylate
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + magnesium salicylate

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • mannitol
  • Cysto-Conray II (iothalamate meglumine)
    +
    mannitol
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + mannitol

    use alternative or monitor renal function if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. mannitol levels, risk of nephrotoxicity, neurotoxicity (including life-threatening), other adverse effects (additive effects)

  • meclofenamate
  • Cysto-Conray II (iothalamate meglumine)
    +
    meclofenamate
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + meclofenamate

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective meclofenamate dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • medroxyprogesterone (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    medroxyprogesterone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + medroxyprogesterone (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • medroxyprogesterone (hormone replacement)
  • Cysto-Conray II (iothalamate meglumine)
    +
    medroxyprogesterone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + medroxyprogesterone (hormone replacement)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • mefenamic acid
  • Cysto-Conray II (iothalamate meglumine)
    +
    mefenamic acid
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + mefenamic acid

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective mefenamic acid dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • megestrol
  • Cysto-Conray II (iothalamate meglumine)
    +
    megestrol
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + megestrol

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • meloxicam
  • Cysto-Conray II (iothalamate meglumine)
    +
    meloxicam
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + meloxicam

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective meloxicam dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • menotropins
  • Cysto-Conray II (iothalamate meglumine)
    +
    menotropins
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + menotropins

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • mesalamine
  • Cysto-Conray II (iothalamate meglumine)
    +
    mesalamine
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + mesalamine

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • mesalamine rectal
  • Cysto-Conray II (iothalamate meglumine)
    +
    mesalamine rectal
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + mesalamine rectal

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • methotrexate
  • Cysto-Conray II (iothalamate meglumine)
    +
    methotrexate
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + methotrexate

    use alternative or monitor CBC, renal function if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • methoxy polyethylene glycol-epoetin beta
  • Cysto-Conray II (iothalamate meglumine)
    +
    methoxy polyethylene glycol-epoetin beta
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + methoxy polyethylene glycol-epoetin beta

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • methyltestosterone
  • Cysto-Conray II (iothalamate meglumine)
    +
    methyltestosterone
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + methyltestosterone

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • metolazone
  • Cysto-Conray II (iothalamate meglumine)
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + metolazone

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • mitomycin
  • Cysto-Conray II (iothalamate meglumine)
    +
    mitomycin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + mitomycin

    if IV iothalamate meglumine use, monitor renal function; risk may be lower w/ intravesical mitomycin administration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • moexipril
  • Cysto-Conray II (iothalamate meglumine)
    +
    moexipril
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + moexipril

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • momelotinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    momelotinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + momelotinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • nabumetone
  • Cysto-Conray II (iothalamate meglumine)
    +
    nabumetone
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + nabumetone

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective nabumetone dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • naproxen
  • Cysto-Conray II (iothalamate meglumine)
    +
    naproxen
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + naproxen

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective naproxen dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • necitumumab
  • Cysto-Conray II (iothalamate meglumine)
    +
    necitumumab
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + necitumumab

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • neomycin
  • Cysto-Conray II (iothalamate meglumine)
    +
    neomycin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + neomycin

    if IV iothalamate meglumine use and compromised gut wall allows for neomycin absorption, monitor renal function, ototoxicity; retrograde cystography and cystourethrography use OK: combo may incr. neomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • nintedanib
  • Cysto-Conray II (iothalamate meglumine)
    +
    nintedanib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + nintedanib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • norelgestromin (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    norelgestromin (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + norelgestromin (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • norethindrone (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    norethindrone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + norethindrone (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • norethindrone (hormone replacement)
  • Cysto-Conray II (iothalamate meglumine)
    +
    norethindrone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + norethindrone (hormone replacement)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • norgestimate (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    norgestimate (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + norgestimate (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • norgestrel (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    norgestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + norgestrel (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • nusinersen
  • Cysto-Conray II (iothalamate meglumine)
    +
    nusinersen
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + nusinersen

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • obinutuzumab
  • Cysto-Conray II (iothalamate meglumine)
    +
    obinutuzumab
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + obinutuzumab

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • olaparib
  • Cysto-Conray II (iothalamate meglumine)
    +
    olaparib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + olaparib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • olmesartan medoxomil
  • Cysto-Conray II (iothalamate meglumine)
    +
    olmesartan medoxomil
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + olmesartan medoxomil

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • olsalazine
  • Cysto-Conray II (iothalamate meglumine)
    +
    olsalazine
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + olsalazine

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • ospemifene
  • Cysto-Conray II (iothalamate meglumine)
    +
    ospemifene
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ospemifene

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • oxaprozin
  • Cysto-Conray II (iothalamate meglumine)
    +
    oxaprozin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + oxaprozin

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective oxaprozin dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • pacritinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    pacritinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + pacritinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • pamidronate
  • Cysto-Conray II (iothalamate meglumine)
    +
    pamidronate
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + pamidronate

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. pamidronate levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • paromomycin
  • Cysto-Conray II (iothalamate meglumine)
    +
    paromomycin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + paromomycin

    if IV iothalamate meglumine use and compromised gut wall allows for paromomycin absorption, monitor renal function, ototoxicity; retrograde cystography and cystourethrography use OK: combo may incr. paromomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • pazopanib
  • Cysto-Conray II (iothalamate meglumine)
    +
    pazopanib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + pazopanib

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • pegaspargase
  • Cysto-Conray II (iothalamate meglumine)
    +
    pegaspargase
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + pegaspargase

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • pemetrexed
  • Cysto-Conray II (iothalamate meglumine)
    +
    pemetrexed
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + pemetrexed

    if IV iothalamate meglumine use, monitor CBC, renal function; retrograde cystography and cystourethrography use OK: combo may incr. pemetrexed levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • penicillamine
  • Cysto-Conray II (iothalamate meglumine)
    +
    penicillamine
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + penicillamine

    if IV iothalamate meglumine use, monitor CBC, renal function; retrograde cystography and cystourethrography use OK: combo may incr. penicillamine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • pentostatin
  • Cysto-Conray II (iothalamate meglumine)
    +
    pentostatin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + pentostatin

    if IV iothalamate meglumine use, monitor CBC, renal function; retrograde cystography and cystourethrography use OK: combo may incr. pentostatin levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • perindopril
  • Cysto-Conray II (iothalamate meglumine)
    +
    perindopril
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + perindopril

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • piroxicam
  • Cysto-Conray II (iothalamate meglumine)
    +
    piroxicam
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + piroxicam

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective piroxicam dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • plazomicin
  • Cysto-Conray II (iothalamate meglumine)
    +
    plazomicin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + plazomicin

    if IV iothalamate meglumine use, monitor plazomicin levels, renal function, ototoxicity; retrograde cystography and cystourethrography use OK: combo may incr. plazomicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • polyethylene glycol
  • Cysto-Conray II (iothalamate meglumine)
    +
    polyethylene glycol
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + polyethylene glycol

    if IV iothalamate meglumine use, monitor renal function, especially if polyethylene glycol bowel prep use; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • polyethylene glycol/electrolytes
  • Cysto-Conray II (iothalamate meglumine)
    +
    polyethylene glycol/ electrolytes
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + polyethylene glycol/ electrolytes

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • pomalidomide
  • Cysto-Conray II (iothalamate meglumine)
    +
    pomalidomide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + pomalidomide

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • ponatinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    ponatinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ponatinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • porfimer
  • Cysto-Conray II (iothalamate meglumine)
    +
    porfimer
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + porfimer

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • progesterone (hormone replacement)
  • Cysto-Conray II (iothalamate meglumine)
    +
    progesterone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + progesterone (hormone replacement)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • progesterone vaginal (hormone replacement)
  • Cysto-Conray II (iothalamate meglumine)
    +
    progesterone vaginal (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + progesterone vaginal (hormone replacement)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • prothrombin complex concentrate (human)
  • Cysto-Conray II (iothalamate meglumine)
    +
    prothrombin complex concentrate (human)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + prothrombin complex concentrate (human)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • quinapril
  • Cysto-Conray II (iothalamate meglumine)
    +
    quinapril
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + quinapril

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • raloxifene
  • Cysto-Conray II (iothalamate meglumine)
    +
    raloxifene
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + raloxifene

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • ramipril
  • Cysto-Conray II (iothalamate meglumine)
    +
    ramipril
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ramipril

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • ramucirumab
  • Cysto-Conray II (iothalamate meglumine)
    +
    ramucirumab
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ramucirumab

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • ranibizumab
  • Cysto-Conray II (iothalamate meglumine)
    +
    ranibizumab
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ranibizumab

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; risk may be lower if ocular implant use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • Rho(D) immune globulin
  • Cysto-Conray II (iothalamate meglumine)
    +
    Rho(D) immune globulin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + Rho(D) immune globulin

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest Rho(D) immune globulin infusion rate possible; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • ritlecitinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    ritlecitinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ritlecitinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • rituximab
  • Cysto-Conray II (iothalamate meglumine)
    +
    rituximab
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + rituximab

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • romiplostim
  • Cysto-Conray II (iothalamate meglumine)
    +
    romiplostim
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + romiplostim

    if IV iothalamate meglumine use, monitor platelets, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • ropeginterferon alfa-2b
  • Cysto-Conray II (iothalamate meglumine)
    +
    ropeginterferon alfa-2b
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ropeginterferon alfa-2b

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • ruxolitinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    ruxolitinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ruxolitinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • ruxolitinib topical
  • Cysto-Conray II (iothalamate meglumine)
    +
    ruxolitinib topical
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ruxolitinib topical

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • salsalate
  • Cysto-Conray II (iothalamate meglumine)
    +
    salsalate
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + salsalate

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • segesterone (contraceptive)
  • Cysto-Conray II (iothalamate meglumine)
    +
    segesterone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + segesterone (contraceptive)

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially with concomitant estrogen use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • sipuleucel-T
  • Cysto-Conray II (iothalamate meglumine)
    +
    sipuleucel-T
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + sipuleucel-T

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • sirolimus
  • Cysto-Conray II (iothalamate meglumine)
    +
    sirolimus
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + sirolimus

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • sitagliptin
  • Cysto-Conray II (iothalamate meglumine)
    +
    sitagliptin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + sitagliptin

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • sodium tetradecyl sulfate
  • Cysto-Conray II (iothalamate meglumine)
    +
    sodium tetradecyl sulfate
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + sodium tetradecyl sulfate

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • sotatercept
  • Cysto-Conray II (iothalamate meglumine)
    +
    sotatercept
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + sotatercept

    if IV iothalamate meglumine use, monitor Hgb, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • sparsentan
  • Cysto-Conray II (iothalamate meglumine)
    +
    sparsentan
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + sparsentan

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • spironolactone
  • Cysto-Conray II (iothalamate meglumine)
    +
    spironolactone
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + spironolactone

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • sulfate bowel prep
  • Cysto-Conray II (iothalamate meglumine)
    +
    sulfate bowel prep
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + sulfate bowel prep

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • sulindac
  • Cysto-Conray II (iothalamate meglumine)
    +
    sulindac
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + sulindac

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective sulindac dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • sunitinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + sunitinib

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • tacrolimus
  • Cysto-Conray II (iothalamate meglumine)
    +
    tacrolimus
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + tacrolimus

    if IV iothalamate meglumine use, monitor tacrolimus levels, renal function; retrograde cystography and cystourethrography use OK: combo may incr. tacrolimus levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • tamoxifen
  • Cysto-Conray II (iothalamate meglumine)
    +
    tamoxifen
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + tamoxifen

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • telavancin
  • Cysto-Conray II (iothalamate meglumine)
    +
    telavancin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + telavancin

    if IV iothalamate meglumine use, monitor ECG, renal function; retrograde cystography and cystourethrography use OK: combo may incr. telavancin levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (additive effects)

  • telmisartan
  • Cysto-Conray II (iothalamate meglumine)
    +
    telmisartan
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + telmisartan

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • temsirolimus
  • Cysto-Conray II (iothalamate meglumine)
    +
    temsirolimus
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + temsirolimus

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • tenofovir alafenamide
  • Cysto-Conray II (iothalamate meglumine)
    +
    tenofovir alafenamide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + tenofovir alafenamide

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • tenofovir disoproxil
  • Cysto-Conray II (iothalamate meglumine)
    +
    tenofovir disoproxil
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + tenofovir disoproxil

    use alternative or monitor renal function if IV iothalamate meglumine use; retrograde cystography and cystourethrography use OK: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • testosterone
  • Cysto-Conray II (iothalamate meglumine)
    +
    testosterone
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + testosterone

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • thalidomide
  • Cysto-Conray II (iothalamate meglumine)
    +
    thalidomide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + thalidomide

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • tiopronin
  • Cysto-Conray II (iothalamate meglumine)
    +
    tiopronin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + tiopronin

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • tivozanib
  • Cysto-Conray II (iothalamate meglumine)
    +
    tivozanib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + tivozanib

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • tofacitinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    tofacitinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + tofacitinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • tolmetin
  • Cysto-Conray II (iothalamate meglumine)
    +
    tolmetin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + tolmetin

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest effective tolmetin dose, shortest effective tx duration; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • toremifene
  • Cysto-Conray II (iothalamate meglumine)
    +
    toremifene
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + toremifene

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • torsemide
  • Cysto-Conray II (iothalamate meglumine)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + torsemide

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • trametinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    trametinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + trametinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially in combo with dabrafenib; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • trandolapril
  • Cysto-Conray II (iothalamate meglumine)
    +
    trandolapril
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + trandolapril

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • tretinoin
  • Cysto-Conray II (iothalamate meglumine)
    +
    tretinoin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + tretinoin

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms, especially during 1st month of tretinoin use; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • triamterene
  • Cysto-Conray II (iothalamate meglumine)
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + triamterene

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • upadacitinib
  • Cysto-Conray II (iothalamate meglumine)
    +
    upadacitinib
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + upadacitinib

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • vadadustat
  • Cysto-Conray II (iothalamate meglumine)
    +
    vadadustat
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + vadadustat

    if IV iothalamate meglumine use, monitor Hgb, thrombosis signs/symptoms; use lowest effective vadadustat dose; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • valacyclovir
  • Cysto-Conray II (iothalamate meglumine)
    +
    valacyclovir
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + valacyclovir

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • valoctocogene roxaparvovec
  • Cysto-Conray II (iothalamate meglumine)
    +
    valoctocogene roxaparvovec
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + valoctocogene roxaparvovec

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • valsartan
  • Cysto-Conray II (iothalamate meglumine)
    +
    valsartan
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + valsartan

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • vamorolone
  • Cysto-Conray II (iothalamate meglumine)
    +
    vamorolone
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + vamorolone

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • vancomycin
  • Cysto-Conray II (iothalamate meglumine)
    +
    vancomycin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + vancomycin

    VANCOMYCIN IV: if IV iothalamate meglumine use, monitor renal function, vancomycin levels, ototoxicity; VANCOMYCIN PO: if IV iothalamate meglumine use, consider monitoring renal function, vancomycin levels, ototoxicity in pts w/ severe renal impairment, severe intestinal inflammation, or prolonged course >2 g/day; retrograde cystography and cystourethrography use OK: combo may incr. vancomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects; increased oral vancomycin absorption if inflamed or compromised gut mucosa)

  • varicella zoster immune globulin
  • Cysto-Conray II (iothalamate meglumine)
    +
    varicella zoster immune globulin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + varicella zoster immune globulin

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • voclosporin
  • Cysto-Conray II (iothalamate meglumine)
    +
    voclosporin
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + voclosporin

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • von Willebrand factor
  • Cysto-Conray II (iothalamate meglumine)
    +
    von Willebrand factor
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + von Willebrand factor

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • vorinostat
  • Cysto-Conray II (iothalamate meglumine)
    +
    vorinostat
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + vorinostat

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

  • willow bark
  • Cysto-Conray II (iothalamate meglumine)
    +
    willow bark
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + willow bark

    if IV iothalamate meglumine use, monitor renal function, especially with high-dose willow bark; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects, willow bark may contain salicylates)

  • ziv-aflibercept
  • Cysto-Conray II (iothalamate meglumine)
    +
    ziv-aflibercept
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + ziv-aflibercept

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • zoledronic acid
  • Cysto-Conray II (iothalamate meglumine)
    +
    zoledronic acid
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + zoledronic acid

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. zoledronic acid levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • zonisamide
  • Cysto-Conray II (iothalamate meglumine)
    +
    zonisamide
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + zonisamide

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • zopapogene imadenovec
  • Cysto-Conray II (iothalamate meglumine)
    +
    zopapogene imadenovec
    1 interaction

    Monitor/Modify Tx

    iothalamate meglumine + zopapogene imadenovec

    if IV iothalamate meglumine use, monitor thrombosis signs/symptoms; retrograde cystography and cystourethrography use OK: combo may incr. risk of thromboembolism (additive effects)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@1169386e
  • hypersensitivity reaction
  • anaphylaxis

Common Reactions

    com.epocrates.rxweb.beans.EmptyCollection@1eeac1b

    may occur but none reported

Safety/Monitoring .

Monitoring Parameters
no routine tests recommended

Pregnancy/Lactation .

Pregnancy

Clinical Summary

may use during pregnancy; risk of fetal harm not expected based on limited human data and minimal systemic absorption

Lactation

Clinical Summary

may use while breastfeeding; no human data available, though risk of infant harm not expected based on minimal drug excretion into milk; no human data available to assess effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@459ff079

Metabolism: for iothalamate: none; CYP450: none

Excretion: for iothalamate: urine primarily (100% unchanged); Half-life: 90min

Subclass: Contrast Agents

Mechanism of Action
for iothalamate: attenuates X-ray beams and opacifies vessels and anatomical structures, enhancing visualization of normal and pathological tissue (nonionic iodine-based contrast medium)

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Guerbet LLC

com.epocrates.rxweb.beans.DrugOtherInfoBean@7d228afe

DEA/FDA: Rx

Retail Price

This information is currently not available for this drug.

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information